Ken Griffin Fate Therapeutics Inc Call Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	BUY	$0.79 - $1.87 $8,611 - $20,383	10,900 Added 68.99%	26,700 $21,000
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.35 $19,481 - $40,535	12,100 Added 327.03%	15,800 $26,000
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $1,872 - $3,342	600 Added 19.35%	3,700 $12,000
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $33,904 - $73,632	-10,400 Reduced 77.04%	3,100 $10,000
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $42,480 - $100,200	12,000 Added 800.0%	13,500 $99,000
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $990 - $2,364	600 Added 66.67%	1,500 $5,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $16,160 - $40,320	-8,000 Reduced 89.89%	900 $1,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $59,976 - $83,034	-12,600 Reduced 58.6%	8,900 $42,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $47,064 - $123,431	-11,100 Reduced 34.05%	21,500 $122,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $36,482 - $88,171	-3,700 Reduced 10.19%	32,600 $328,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $122,032 - $209,148	5,800 Added 19.02%	36,300 $813,000

147

88.3M

56.7K

5.4K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $98M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.